Paul Tudor Jones's PRME Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 62,981 shares of Prime Medicine, Inc. (PRME) worth $348,915, representing 0.00% of the portfolio. First purchased in 2024-Q1, this short-term holding has been held for 5 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in PRME for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 62,981 shares. Largest reduction occurred in Q2 2024, reducing 61,295 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Prime Medicine (PRME) Holding Value Over Time
Track share changes against reported price movement
Quarterly Prime Medicine (PRME) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2024 | +61,295 | New Buy | 61,295 | $7.00 |
| Q2 2024 | -61,295 | Sold Out | 0 | $0.00 |
| Q1 2025 | +60,368 | New Buy | 60,368 | $1.99 |
| Q2 2025 | -60,368 | Sold Out | 0 | $0.00 |
| Q3 2025 | +62,981 | New Buy | 62,981 | $5.54 |
Paul Tudor Jones's Prime Medicine Investment FAQs
Paul Tudor Jones first purchased Prime Medicine, Inc. (PRME) in Q1 2024, acquiring 61,295 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Prime Medicine, Inc. (PRME) for 5 quarters since Q1 2024.
Paul Tudor Jones's largest addition to Prime Medicine, Inc. (PRME) was in Q3 2025, adding 62,981 shares worth $348,915.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 62,981 shares of Prime Medicine, Inc. (PRME), valued at approximately $348,915.
As of the Q3 2025 filing, Prime Medicine, Inc. (PRME) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Prime Medicine, Inc. (PRME) was 62,981 shares, as reported at the end of Q3 2025.